SLCTR_2015_002
A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects With Systemic Lupus Erythematosus
Anthera Pharmaceuticals, Inc·Phase 3·Sri Lanka Clinical Trials RegistrySuspended
Study focus
- Disease/Condition
- Systemic Lupus Erythematosus
- Study type
- Interventional
Sponsor & location
- Primary sponsor
- Anthera Pharmaceuticals, Inc
- Location
- Belarus, Brazil, Colombia, Georgia, Guatemala, HongKong, North Korea, Malaysia, Mexico, Philippines,
Timeline & enrollment
- Phase
- Phase 3
- Start date
- Apr 09, 2015
- End date
- N/A
ICD-10 classifications
Systemic lupus erythematosusSystemic lupus erythematosus, unspecifiedLupus erythematosusSystemic lupus erythematosus with organ or system involvementOther forms of systemic lupus erythematosus
Data source
- Registry
- Sri Lanka Clinical Trials Registry
- Trial ID
- SLCTR_2015_002
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for SLCTR_2015_002 through Pure Global AI's free database. This Phase 3 trial is sponsored by Anthera Pharmaceuticals, Inc and is currently Suspended. The study focuses on Systemic Lupus Erythematosus.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Sri Lanka Clinical Trials Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.